Delivery Order SPE2DB22D2006-SPE2DB25FW3XK
- Not listed
- The Defense Logistics Agency awarded a $4,831.85 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of UBRELVY 100 mg tablets in unit dose packaging (10 tablets per dose). This is a firm fixed-price delivery order with no set-aside designation, representing a competitively awarded contract. The order is scheduled for completion by July 29, 2025, with performance taking place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for 4,568,984,056 units of UBRELVY 100 mg tablets in unit dose packages of 16 tablets, valued at $59,129.24. This competitively awarded, firm fixed-price delivery order has an ultimate completion date of August 5, 2025, and is being fulfilled from the vendor's corporate office location in Conshohocken, Pennsylvania. UBRELVY is a migraine treatment medication, and this delivery order represents fulfillment...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of UBRELVY 50 mg tablets in unit dose packaging (10 count). This order, valued at $5,439.62 with a firm fixed price structure, represents a non-competitive delivery order issued under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, with a...
- The Defense Logistics Agency awarded a delivery order valued at $29,146.75 to AmerisourceBergen Drug Corp for UBRELVY 100 MG tablets (16-count unit dose packaging) on August 13, 2025, with an ultimate completion date of August 14, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be fulfilled at the contractor's facility in Conshohocken, Pennsylvania. UBRELVY is a migraine treatment medication, reflecting AmerisourceBergen's role as a...
- The Defense Logistics Agency awarded a delivery order valued at $2,199.96 to AmerisourceBergen Drug Corp for UBRELVY 100 mg tablets (10 unit dose packages) on August 14, 2025, with an ultimate completion date of August 15, 2025. This is a firm fixed price delivery order with no set-aside designation, awarded competitively under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) vehicle with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and running through December...
- The Defense Logistics Agency awarded a delivery order valued at $1,217.32 to AmerisourceBergen Drug Corp for UBRELVY 50 mg tablets (10 unit dose packages) on August 8, 2025, with an ultimate completion date of August 11, 2025. This firm fixed price delivery order represents a non-set-aside competitive award and reflects the pharmaceutical distribution services AmerisourceBergen provides to federal medical procurement. The place of performance is located in Conshohocken, Pennsylvania, where...
- The Defense Logistics Agency awarded a $26,179.43 delivery order to AmerisourceBergen Drug Corp for UBRELVY 100 mg tablets (16-count unit dose packaging) on July 23, 2025, with completion scheduled for July 24, 2025. This competitively awarded, firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The place of performance is...
- The Defense Logistics Agency awarded a delivery order valued at $3,420.49 to AmerisourceBergen Drug Corp for the supply of UBRELVY (an FDA-approved migraine treatment) in 100 mg tablet form on August 20, 2025, with completion expected by August 21, 2025. This non-competitive delivery order utilizes firm fixed pricing and represents a child contract under AmerisourceBergen's broader Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,270.92 to AmerisourceBergen Drug Corp for UBRELVY 100 mg tablets (10-count unit dose packaging) with an ultimate completion date of August 1, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded through an open process. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. UBRELVY is a migraine treatment medication,...
- The Defense Logistics Agency awarded a delivery order valued at $2,850.02 to AmerisourceBergen Drug Corp on August 27, 2025, for the supply of UBRELVY 100 mg tablets in unit dose packaging (16 count). This is a firm fixed-price delivery order with no set-aside designation, indicating competitive award through open competition. The contract is scheduled for ultimate completion on August 28, 2025, with performance taking place at the vendor's corporate office in Conshohocken, Pennsylvania. This...
- SPE2DB22D2006Indefinite Delivery Contract
- SPE2DB22D2006-SPE2DB25FW3XKDelivery Order
The Defense Logistics Agency awarded a $15,567.60 delivery order to AmerisourceBergen Drug Corp on August 28, 2025, for the supply of UBRELVY 100 mg tablets (unit dose, 10s). This is a firm fixed price, competitively awarded contract with an ultimate completion date of August 29, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. UBRELVY is a prescription migraine treatment, indicating this delivery order supports military or federal healthcare pharmaceutical needs through DLA's medical supply chain. This delivery order represents a child contract action under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. This IDC serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply a broad range of medications, vaccines, and medical supplies to support military healthcare programs. AmerisourceBergen, a major pharmaceutical distributor headquartered in Pennsylvania, has demonstrated capability to meet federal procurement requirements through open competition and currently serves as a critical vendor for Defense Health Agency and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $15.6k | 8/28/25 |